Signature Estate & Investment Advisors LLC Lifted Holding in C.R. Bard, Inc. (BCR)

Signature Estate & Investment Advisors LLC Lifted Holding in C.R. Bard, Inc. (BCR)

Signature Estate & Investment Advisors LLC boosted its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 80.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,375 shares of the company’s stock after buying an additional 614 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in C.R. Bard were worth $308,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of BCR. LS Investment Advisors LLC increased its stake in shares of C.R. Bard by 7.4% in the second quarter. LS Investment Advisors LLC now owns 19,434 shares of the company’s stock valued at $4,570,000 after buying an additional 1,340 shares during the period. Strs Ohio increased its stake in shares of C.R. Bard by 8.8% in the second quarter. Strs Ohio now owns 7,448 shares of the company’s stock valued at $1,751,000 after buying an additional 603 shares during the period. Candriam Luxembourg S.C.A. increased its stake in shares of C.R. Bard by 9.8% in the second quarter. Candriam Luxembourg S.C.A. now owns 2,745 shares of the company’s stock valued at $646,000 after buying an additional 244 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of C.R. Bard by 7.8% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,474 shares of the company’s stock valued at $582,000 after buying an additional 178 shares during the period. Finally, Savant Capital LLC acquired a new stake in shares of C.R. Bard during the second quarter valued at about $391,000. 87.56% of the stock is currently owned by institutional investors and hedge funds.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 237.33 on Wednesday. C.R. Bard, Inc. has a 52-week low of $177.47 and a 52-week high of $240.59. The firm has a market capitalization of $17.45 billion, a PE ratio of 33.76 and a beta of 0.65. The stock has a 50 day moving average price of $228.03 and a 200-day moving average price of $221.75.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, January 26th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.03. C.R. Bard had a return on equity of 48.48% and a net margin of 14.31%. The business earned $967.10 million during the quarter, compared to analyst estimates of $956.12 million. During the same period in the previous year, the company posted $2.43 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. Equities analysts forecast that C.R. Bard, Inc. will post $11.57 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 3rd. Investors of record on Monday, January 23rd will be given a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Thursday, January 19th. C.R. Bard’s payout ratio is 14.77%.

Several equities research analysts have issued reports on BCR shares. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $241.00 price target for the company in a report on Thursday, October 27th. BMO Capital Markets upgraded C.R. Bard from a “market perform” rating to an “outperform” rating and set a $245.00 price objective for the company in a report on Monday, December 12th. They noted that the move was a valuation call. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Friday, January 27th. Barclays PLC reiterated a “hold” rating and set a $245.00 price objective on shares of C.R. Bard in a report on Sunday. Finally, Morgan Stanley upgraded C.R. Bard from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $240.00 to $260.00 in a report on Tuesday, January 3rd. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $244.14.

In related news, insider John P. Groetelaars sold 573 shares of the business’s stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $235.00, for a total value of $134,655.00. Following the completion of the sale, the insider now directly owns 16,554 shares of the company’s stock, valued at approximately $3,890,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP John A. Deford sold 15,883 shares of the business’s stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $218.03, for a total value of $3,462,970.49. The disclosure for this sale can be found here. Insiders sold a total of 41,747 shares of company stock valued at $9,214,780 over the last ninety days. 0.97% of the stock is currently owned by corporate insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Related posts

Leave a Comment